For cancer, there are many treatments and options - if - your doctor gets the right information, which only happens - if - you get tested for the right thing at the right time. Unfortunately, that rarely happens today as most cancers show no physical symptoms until advanced stages.
That's why we need a paradigm shift in cancer detection. A shift from the current methods of sporadic testing for cancers - to regularly monitoring. And that's exactly what next gen liquid biopsy using Cardea's BPU™ platform offers.
Our Commercial Partnerships are designed for those who are ready to hit the ground running with their Powered by Cardea™ service. Commercial partners gain access to our current suite of technology to provide the infrastructure for their assay services. As we develop more technology modules, they will become available to our Commercial Partners and used to expand and build their offerings.